The latest iteration of the multi-application platform adds new pulsed-light features and is approved to treat over 30 indications for skin and hair removal.
Lumenis Be Ltd, an energy-based medical device company, unveiled the latest edition of its multi-application aesthetic platform, the Stellar M22 with XPL Technology, powered by four technologies and approved to treat over 30 different indications.
Stellar M22 with XPL, the latest innovation from the inventors of IPL, is designed to enable versatile treatment workflows for any age, gender, and skin type. Underscoring its clinical impact, Lumenis showcased positive clinical data at the 2025 Annual American Society for Dermatologic Surgery (ASDS) Meeting, demonstrating the platform’s ability to achieve at least a 70% improvement in one XPL session.
Key system innovations include:
- XPL (expert pulsed light) Technology: Latest advancement in pulsed light technology featuring eight expert filters, sub-pulsing technology, and advanced pulse design for versatility and precision control of each variable of the pulse parameters
- XPL Glide Mode: New feature designed for precise, faster treatments in motion with increased comfort and high-speed passes, suitable for skin rejuvenation treatments and coverage of larger treatment areas
- Diverse Treatment Modalities: Addresses uneven skin tone and texture improvement, large vascular lesions, and dark tattoo removal
- ResurFX BrushFX Mode: New capability designed to deliver natural-looking texture effects with airbrush-style blending
- Hybrid treatment modalities: Featuring treatments such as PhotoFABULOUS, which combines two Stellar technologies—XPL and ResurFX—for skin rejuvenation, and SmoothGlo, which pairs two of Lumenis’s systems—Stellar XPL and triLift RF Microneedling—for improvement in skin texture, tone, and volume
- 850-plus Built-in Expert Protocols: Designed to simplify delegation and ensure repeatable, consistent outcomes across treatment teams
“At Lumenis, innovation is at the heart of everything we do, and the new Stellar M22 with XPL Technology is a shining example of that commitment. This powerful, multi-application platform meets the evolving needs of today’s aesthetic providers, offering unparalleled versatility and clinically proven efficacy across a wide range of skin concerns,” says Tzipi Ozer-Armon, CEO of Lumenis, in a release.
At ASDS 2025, the company demonstrated the system’s power in a retrospective evaluation by highlighting clinical data of achieving clearance of cutaneous lesions (76-100% cleared) after one session of XPL treatment for both vascular and pigmented lesions. After one pass of XPL treatment, patients achieved good clearance (51-75%).
“The Stellar M22, backed by 30 years of refinement, delivers consistently outstanding clinical results. Having used an M22 for the past 15 years with great results, I am amazed at how much the Stellar surpasses its predecessor in every way,” says Dr Gilly Munavalli, director and founder of Dermatology, Laser, and Vein Specialists, in a release. “Enhanced by expert pulsed light technology, its advanced pulse design and practitioner-focused usability make it an indispensable tool in my practice. The new XPL Glide mode further expands its capabilities with the ability to perform treatments more quickly, comfortably, and with minimal downtime.”
ID 89384378 © Igor Mojzes | Dreamstime.com
